Literature DB >> 14769700

Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study.

Finlay A McAlister1, Justin Ezekowitz, Marcello Tonelli, Paul W Armstrong.   

Abstract

BACKGROUND: The prevalence, prognostic import, and impact of renal insufficiency on the benefits of ACE inhibitors and beta-blockers in community-dwelling patients with heart failure are uncertain. METHODS AND
RESULTS: We analyzed data from a prospective cohort of 754 patients with heart failure who had ejection fraction, serum creatinine, and weight measured at baseline. Median age was 69 years, and 43% had an ejection fraction > or =35%. By the Cockcroft-Gault equation, 118 patients (16%) had creatinine clearances < or =30 mL/min and 301 (40%) had creatinine clearances between 30 and 59 mL/min. During follow-up (median 926 days), 385 patients (37%) died. Even after adjustment for all other prognostic factors, survival was significantly associated with renal function (P=0.002) in patients with either systolic or diastolic dysfunction; patients exhibited a 1% increase in mortality for each 1-mL/min decrease in creatinine clearance. The associations with 1-year mortality reductions were similar for ACE inhibitors (OR 0.46 [95% CI 0.26 to 0.82] versus OR 0.28 [95% CI 0.11 to 0.70]) and beta-blockers (OR 0.40 [95% CI 0.23 to 0.70] versus OR 0.41 [95% CI 0.19 to 0.85]) in patients with creatinine clearances <60 mL/min versus > or =60 mL/min, although these drugs were used less frequently in patients with renal insufficiency.
CONCLUSIONS: Renal insufficiency is more prevalent in patients with heart failure than previously reported and is an independent prognostic factor in diastolic and systolic dysfunction. ACE inhibitors and beta-blockers were associated with similar reductions in mortality in patients with and without renal insufficiency.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14769700     DOI: 10.1161/01.CIR.0000116764.53225.A9

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  183 in total

1.  Approach to cardiovascular disease prevention in patients with chronic kidney disease.

Authors:  Cristina Karohl; Paolo Raggi
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-08

2.  Cardiorenal Resynchronization Therapy: Strengthening the Heart and Kidneys.

Authors:  Edmond K Obeng-Gyimah; Rajat Deo
Journal:  Clin J Am Soc Nephrol       Date:  2015-09-25       Impact factor: 8.237

3.  Atrial fibrillation: a leading cause of heart failure-related hospitalizations; a dual epidemic.

Authors:  Asrar Ahmed; Waqas Ullah; Ishtiaq Hussain; Sohaib Roomi; Yasar Sattar; Faizan Ahmed; Rehan Saeed; Ammar Ashfaq
Journal:  Am J Cardiovasc Dis       Date:  2019-10-15

4.  Peritoneal dialysis reduces the number of hospitalization days in heart failure patients refractory to diuretics.

Authors:  Cécile Courivaud; Amir Kazory; Thomas Crépin; Raymond Azar; Catherine Bresson-Vautrin; Jean-Marc Chalopin; Didier Ducloux
Journal:  Perit Dial Int       Date:  2013-09-01       Impact factor: 1.756

5.  The natural history of preclinical diastolic dysfunction: a population-based study.

Authors:  Mark W Vogel; Joshua P Slusser; David O Hodge; Horng H Chen
Journal:  Circ Heart Fail       Date:  2012-01-25       Impact factor: 8.790

6.  Cardiac Resynchronization Therapy in CKD Stage 4 Patients.

Authors:  Ulas Höke; Mand J H Khidir; Enno T van der Velde; Martin J Schalij; Jeroen J Bax; Victoria Delgado; Nina Ajmone Marsan
Journal:  Clin J Am Soc Nephrol       Date:  2015-09-25       Impact factor: 8.237

Review 7.  The contribution of observational studies to the knowledge of drug effectiveness in heart failure.

Authors:  Daniela Dobre; Dirk J van Veldhuisen; Mike J L DeJongste; Eric van Sonderen; Olaf H Klungel; Robbert Sanderman; Adelita V Ranchor; Flora M Haaijer-Ruskamp
Journal:  Br J Clin Pharmacol       Date:  2007-08-31       Impact factor: 4.335

8.  Comorbid Heart Failure and Renal Impairment: Epidemiology and Management.

Authors:  Pupalan Iyngkaran; Merlin Thomas; William Majoni; Nagesh S Anavekar; Claudio Ronco
Journal:  Cardiorenal Med       Date:  2012-10-31       Impact factor: 2.041

Review 9.  Heart failure and kidney dysfunction: epidemiology, mechanisms and management.

Authors:  Joerg C Schefold; Gerasimos Filippatos; Gerd Hasenfuss; Stefan D Anker; Stephan von Haehling
Journal:  Nat Rev Nephrol       Date:  2016-08-30       Impact factor: 28.314

Review 10.  Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?

Authors:  A A Tahrani; G I Varughese; J H Scarpello; F W F Hanna
Journal:  BMJ       Date:  2007-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.